Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial.

Enrico TiacciLuca De CarolisEdoardo SimonettiMara MerluzziAntonio BennatiVincenzo Maria PerrielloAlessandra PucciariniAlessia SantiAlessandra VenanziValentina PettirossiGianluca SchiavoniLuisa TasselliStefano AscaniStefano VolpettiBrunangelo Falini

Published in: Leukemia (2021)

Keyphrases

clinical trial
acute myeloid leukemia
study protocol
acute lymphoblastic leukemia
single cell
diffuse large b cell lymphoma
cell therapy
multiple myeloma
bone marrow
hodgkin lymphoma
phase ii
stem cells
randomized controlled trial
metastatic colorectal cancer
wild type